BioCentury
ARTICLE | Company News

Axonyx, Ares-Serono deal

May 8, 2000 7:00 AM UTC

AREB exercised its option to license exclusively AXYX's anti-amyloid peptide technology to develop compounds to treat Alzheimer's disease and other neurological disorders. Under the proposed license a...